This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.
November 13, 2025
At the CHARCOT Congress held in November 2025 in Baveno, Italy, we presented new MSCopilot® analyses.
This medical device is distinguished by its clinically validated ability to classify Multiple Sclerosis (MS) patients by disability level. Its digital biomarkers enable assessment of various symptoms in real-life conditions, providing a score whose correlation with EDSS has been previously demonstrated.
In Chicago, April 18-22, 2026, Ad Scientiam presented 4 scientific posters at the American Academy of Neurology, covering MSCopilot® in MS and ME&MG™ in generalized autoimmune myasthenia.
April 18, 2026
At the Cystic Fibrosis Scientific Days 2025, we presented MuCopilot®, our home monitoring tool based on digital biomarkers measured via smartphone.
March 9, 2026
In Dubai in December 2025, we presented MS-DETECT data on the correlation between MSCopilot® digital biomarkers and traditional clinical assessments.
December 5, 2025
Talk to our experts and discover how our solutions integrate into your practice or studies.